BURCON NUTRASCIENCE CORP (BU.CA) Stock Fundamental Analysis

Canada • Toronto Stock Exchange • TSX:BU • CA1208313009

1.9 CAD
0 (0%)
Last: Feb 4, 2026, 07:00 PM
Fundamental Rating

2

Overall BU gets a fundamental rating of 2 out of 10. We evaluated BU against 27 industry peers in the Chemicals industry. BU may be in some trouble as it scores bad on both profitability and health. BU is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • BU had negative earnings in the past year.
  • In the past year BU has reported a negative cash flow from operations.
  • BU had negative earnings in each of the past 5 years.
  • In the past 5 years BU always reported negative operating cash flow.
BU.CA Yearly Net Income VS EBIT VS OCF VS FCFBU.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -5M -10M -15M -20M -25M

1.2 Ratios

  • The Return On Assets of BU (-45.26%) is worse than 77.78% of its industry peers.
  • BU has a worse Return On Equity (-8604.73%) than 81.48% of its industry peers.
Industry RankSector Rank
ROA -45.26%
ROE -8604.73%
ROIC N/A
ROA(3y)-113.59%
ROA(5y)-75.48%
ROE(3y)-292.02%
ROE(5y)-182.82%
ROIC(3y)N/A
ROIC(5y)N/A
BU.CA Yearly ROA, ROE, ROICBU.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200 -200 400 -400 -600

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for BU so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BU.CA Yearly Profit, Operating, Gross MarginsBU.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -5K -10K -15K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. Health

2.1 Basic Checks

  • BU does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, BU has more shares outstanding
  • Compared to 5 years ago, BU has more shares outstanding
  • Compared to 1 year ago, BU has a worse debt to assets ratio.
BU.CA Yearly Shares OutstandingBU.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M
BU.CA Yearly Total Debt VS Total AssetsBU.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M

2.2 Solvency

  • BU has an Altman-Z score of -9.43. This is a bad value and indicates that BU is not financially healthy and even has some risk of bankruptcy.
  • BU's Altman-Z score of -9.43 is on the low side compared to the rest of the industry. BU is outperformed by 74.07% of its industry peers.
  • A Debt/Equity ratio of 104.05 is on the high side and indicates that BU has dependencies on debt financing.
  • With a Debt to Equity ratio value of 104.05, BU is not doing good in the industry: 81.48% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 104.05
Debt/FCF N/A
Altman-Z -9.43
ROIC/WACCN/A
WACC9.45%
BU.CA Yearly LT Debt VS Equity VS FCFBU.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10M 20M 30M

2.3 Liquidity

  • BU has a Current Ratio of 0.25. This is a bad value and indicates that BU is not financially healthy enough and could expect problems in meeting its short term obligations.
  • BU has a Current ratio of 0.25. This is in the lower half of the industry: BU underperforms 77.78% of its industry peers.
  • A Quick Ratio of 0.21 indicates that BU may have some problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 0.21, BU is doing worse than 81.48% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 0.25
Quick Ratio 0.21
BU.CA Yearly Current Assets VS Current LiabilitesBU.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. Growth

3.1 Past

  • The earnings per share for BU have decreased strongly by -163.63% in the last year.
  • The Revenue has grown by 190.04% in the past year. This is a very strong growth!
  • BU shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 66.28% yearly.
EPS 1Y (TTM)-163.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%15.35%
Revenue 1Y (TTM)190.04%
Revenue growth 3Y30.91%
Revenue growth 5Y66.28%
Sales Q2Q%792.98%

3.2 Future

  • Based on estimates for the next years, BU will show a very strong growth in Earnings Per Share. The EPS will grow by 224.01% on average per year.
  • Based on estimates for the next years, BU will show a very strong growth in Revenue. The Revenue will grow by 228.16% on average per year.
EPS Next Y-803.01%
EPS Next 2Y224.01%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year153.85%
Revenue Next 2Y228.17%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
BU.CA Yearly Revenue VS EstimatesBU.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 5M 10M
BU.CA Yearly EPS VS EstimatesBU.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2020 2021 2022 2023 2024 2025 2026 2027 0 2 -2 4 -4 6 -6

More info and screens

Find the best growth stocksShow best growing peers

3

4. Valuation

4.1 Price/Earnings Ratio

  • BU reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • With a Price/Forward Earnings ratio of 0.29, the valuation of BU can be described as very cheap.
  • 100.00% of the companies in the same industry are more expensive than BU, based on the Price/Forward Earnings ratio.
  • BU is valuated cheaply when we compare the Price/Forward Earnings ratio to 27.50, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 0.29
BU.CA Price Earnings VS Forward Price EarningsBU.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BU.CA Per share dataBU.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

  • A more expensive valuation may be justified as BU's earnings are expected to grow with 224.01% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y224.01%
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for BU!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BURCON NUTRASCIENCE CORP

TSX:BU (2/4/2026, 7:00:00 PM)

1.9

0 (0%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)11-12
Earnings (Next)02-12
Inst Owners5.83%
Inst Owner ChangeN/A
Ins Owners31.02%
Ins Owner ChangeN/A
Market Cap24.11M
Revenue(TTM)803.70K
Net Income(TTM)-11.11M
Analysts84.44
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-359.08%
Min EPS beat(2)-443.69%
Max EPS beat(2)-274.48%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)17.69%
Min Revenue beat(2)-30.64%
Max Revenue beat(2)66.02%
Revenue beat(4)1
Avg Revenue beat(4)-37.08%
Min Revenue beat(4)-95.36%
Max Revenue beat(4)66.02%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 0.29
P/S 30
P/FCF N/A
P/OCF N/A
P/B 186.76
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.98
EYN/A
EPS(NY)6.58
Fwd EY346.41%
FCF(TTM)-0.62
FCFYN/A
OCF(TTM)-0.56
OCFYN/A
SpS0.06
BVpS0.01
TBVpS-0.09
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -45.26%
ROE -8604.73%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-113.59%
ROA(5y)-75.48%
ROE(3y)-292.02%
ROE(5y)-182.82%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 104.05
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 46.09%
Cap/Sales 95.93%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.25
Quick Ratio 0.21
Altman-Z -9.43
F-Score4
WACC9.45%
ROIC/WACCN/A
Cap/Depr(3y)68.17%
Cap/Depr(5y)195.49%
Cap/Sales(3y)82.83%
Cap/Sales(5y)124.04%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-163.63%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%15.35%
EPS Next Y-803.01%
EPS Next 2Y224.01%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)190.04%
Revenue growth 3Y30.91%
Revenue growth 5Y66.28%
Sales Q2Q%792.98%
Revenue Next Year153.85%
Revenue Next 2Y228.17%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-1.09%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year40.58%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-51.36%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-46.69%
OCF growth 3YN/A
OCF growth 5YN/A

BURCON NUTRASCIENCE CORP / BU.CA FAQ

What is the fundamental rating for BU stock?

ChartMill assigns a fundamental rating of 2 / 10 to BU.CA.


What is the valuation status for BU stock?

ChartMill assigns a valuation rating of 3 / 10 to BURCON NUTRASCIENCE CORP (BU.CA). This can be considered as Overvalued.


What is the profitability of BU stock?

BURCON NUTRASCIENCE CORP (BU.CA) has a profitability rating of 0 / 10.


What is the expected EPS growth for BURCON NUTRASCIENCE CORP (BU.CA) stock?

The Earnings per Share (EPS) of BURCON NUTRASCIENCE CORP (BU.CA) is expected to decline by -803.01% in the next year.